Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies

Fineline Cube May 23, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Policy / Regulatory

NHSA Proposes Draft to Enhance Basic Medical Insurance Payment Management for Consumables

Fineline Cube May 23, 2023

The National Healthcare Security Administration (NHSA) has issued a Notice seeking public feedback on draft...

Company Drug

SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody

Fineline Cube May 23, 2023

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...

Policy / Regulatory

China Aims to Establish Basic Elderly Care System by 2025, Outlines Comprehensive Plan

Fineline Cube May 23, 2023

The General Office of the CPC Central Committee and General Office of the State Council...

Company Deals

JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization

Fineline Cube May 22, 2023

China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno,...

Company Drug

HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study

Fineline Cube May 22, 2023

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...

Company Deals

GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment

Fineline Cube May 22, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary,...

Company Drug

Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials

Fineline Cube May 22, 2023

Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates

Fineline Cube May 22, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...

Company Drug

Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC

Fineline Cube May 22, 2023

Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...

Policy / Regulatory

Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement

Fineline Cube May 22, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in...

Company

Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase

Fineline Cube May 22, 2023

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...

Company Drug

Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy

Fineline Cube May 19, 2023

US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...

Company Deals

MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange

Fineline Cube May 19, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin...

Company Deals

Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy

Fineline Cube May 19, 2023

US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...

Company Deals

Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal

Fineline Cube May 19, 2023

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...

Company Deals

International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements

Fineline Cube May 19, 2023

The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development...

Company Medical Device

MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System

Fineline Cube May 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches

Fineline Cube May 19, 2023

A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...

Company Deals

Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope

Fineline Cube May 19, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US...

Posts pagination

1 … 547 548 549 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.